Quality Control/Quality Assurance Reviews for CTSA Submissions

总体UL 1：摘要前沿：堪萨斯大学临床和转化科学研究所 一直是将整个KC地区的转化科学研究人员和利益相关者聚集在一起的催化剂， 以及更远的地方位于KUMC的马里奥卡斯特罗，医学博士，公共卫生硕士的领导下，我们对团队的承诺 科学和多学科合作超越了我们的学术健康科学中心的墙壁 并促进来自不同学科的研究人员在当地合作伙伴学术 机构和附属卫生保健机构（儿童慈善堪萨斯城，密苏里大学堪萨斯分校 堪萨斯大学卫生系统，堪萨斯城医科大学 和生物科学，和堪萨斯州立大学）。Frontiers的愿景是促进和领导国家 努力改变我们进行临床和转化研究（CTR）的方式，并确保研究更加 更快、更有效地转化到护理点，以便有助于改善健康。 具体而言，前沿的目标是：1）与所有利益相关者进行双向合作， 展示和传播跨转化科学领域的进步，确保包容性， 从出生到生命结束的整个生命周期中，复杂多样的人口和个人的融合; 2） 建立一支由多学科调查人员、研究人员和 社区和病人利益相关者在使用转化科学工具，通过创新和创造性的 项目; 3）加强机构和区域基础设施，以加速转化研究。我们 我们将通过利用我们的巨大优势来实现这些目标：a）开发信息学工具， 使电子健康记录数据“为研究做好准备”，并实施基于诊所和社区的登记研究 招募和其他转化研究应用; B）培养和维持强大的病人和 社区参与关系，将支持研究与非洲裔美国人，拉丁美洲人，美国人， 印度，LGBTQ，儿科，老年人，罕见疾病，监狱和农村人口; c）提供创新培训 针对整个CTR劳动力（不仅仅是调查人员）的计划，包括全面的 创业和实施研究培训和创造新的团队科学头脑风暴 机制，将导致多学科的发现项目和d）推进医疗设备和重新- 通过Frontiers' Institute for Advancing Medical开发的新策略， 以产品开发、转化研究和高影响力而闻名全国的创新 与工业界、学术界、政府和疾病慈善合作伙伴的合作。所有边境部队 由一组导航器链接，可供Frontiers调查团队和社区访问 伙伴这些计划使Frontiers能够为实现目标做出贡献，并通过以下方式领导CTSA网络的各项举措： 以技术、计算和健康/疾病知识为基础，推进转化研究。

OVERALL UL1: ABSTRACT Frontiers: University of Kansas Clinical and Translational Science Institute has been a catalyst for bringing together translational science investigators and stakeholders across the KC region, and beyond. Located at KUMC under the leadership of Mario Castro, MD, MPH, our commitment to team science and multidisciplinary collaboration reaches beyond the walls of our academic health science center and promotes collaboration among investigators from diverse disciplines across local partner academic institutions and affiliated health care institutions (Children’s Mercy Kansas City, University of Missouri-Kansas City, Saint Luke’s Health System, The University of Kansas Health System, Kansas City University of Medicine and Biosciences, and Kansas State University). The vision of Frontiers is to contribute to and lead national efforts to transform the way we do clinical and translational research (CTR), and to ensure research is more rapidly and more efficiently translated to the point of care so that it may contribute to improved health. Specifically, Frontiers aims to: 1) Engage in bi-directional collaboration with all stakeholders to develop, demonstrate, and disseminate advances across the translational science spectrum that insures inclusion and integration of complex and diverse populations and individuals across the lifespan from birth to end of life; 2) Create a sustainable translational workforce of multi-disciplinary investigators, research personnel, and community and patient stakeholders in the use of translational science tools through innovative and creative programs; and 3) Strengthen institutional and regional infrastructure to accelerate translational research. We will accomplish these aims by drawing on our considerable strengths: a) developing informatics tools for making EHR data ‘research ready’ and implementing clinic- and community-based registries for study recruitment and other translational research applications; b) nurturing and sustaining strong patient and community engagement relationships that will support research with African American, Latino, American Indian, LGBTQ, pediatric, geriatric, rare disease, prison, and rural populations; c) offering innovative training programs for the entire CTR workforce (not just investigators), including plans for comprehensive entrepreneurship and implementation research training and creating new team science brainstorming mechanisms that will lead to multidisciplinary discovery projects and d) advancing medical devices and re- purposed drugs to patients through novel strategies developed by Frontiers’ Institute for Advancing Medical Innovations that is nationally known for its product development translational research and high impact collaborations with industry, academia, government, and disease philanthropy partners. All Frontiers units are linked by a group of Navigators that can be accessed by Frontiers investigative teams and community partners. These plans position Frontiers to contribute to goals, and lead initiatives of the CTSA network by building on technological, computational, and health/disease knowledge to advance translational research.